Ryvu Therapeutics announced the promotion of Hendrik Nogai, M.D., Chief Medical Officer, and Vatnak Vat-Ho, Chief Business Officer to its Management Board. Dr. Nogai has served as Chief Medical Officer at Ryvu since February 2022. He is a board-certified medical doctor in Hematology/Oncology as well as in Internal Medicine, with almost 10 years of experience in patientcare and basic research in various academic settings.

Besides his clinical expertise, Dr. Nogai has 17 years of industry experience including business consulting at Mercer Management Consulting/Oliver Wyman, a Medical Advisor role at Nordic Biotech Capital ApS, and positions of increasing responsibility at Bayer AG, with his most recent role of Vice President, Global Development Leader NTRK program. Mr. Vat-Ho has been Ryvu's Chief Business Officer since April 2021 and has 20 years of experience in pharma, biotech, as well as capital markets expertise. Vatnak Vat-Ho spent the first 10 years of his professional career in a variety of investment banks and global equity healthcare funds followed by 8 years at Pfizer where he held several roles, concluding in the position of Senior Director/Team Lead, Strategy, Business Development &Alliances in the commercial development organization.

Most recently Mr. Vat-Ho served as Vice President, Business Development at Affimed Inc. where he was responsible for leading partnering activities for both the preclinical and clinical pipeline, as well as serving as alliance manager for the company's collaborations.